Shareholder Class Action

CHICAGO – A class claims in a federal complaint that Akorn Inc.’s executives did not disclose that the pharmaceutical company’s noncompliance with federal data integrity requirements would jeopardize its acquisition by a health care firm, causing share prices to drop 38 percent to $18.65.

%d bloggers like this: